{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:48:53Z","timestamp":1789944533490,"version":"4.0.1"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001537","name":"University of Auckland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001537","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40265-025-02241-6","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:11:26Z","timestamp":1775189486000},"page":"675-718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacological, Natural and Emerging Therapies for Meibomian Gland Dysfunction: A Review"],"prefix":"10.1007","volume":"86","author":[{"given":"Jordan M.","family":"Cooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalika","family":"Bandamwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T. M.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8297-5319","authenticated-orcid":false,"given":"Jennifer P.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"2241_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1167\/iovs.10-6997c","volume":"52","author":"E Knop","year":"2011","unstructured":"Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011;52:1938\u201378.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2241_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/j.1538-9235.1997.tb04573.x","volume":"74","author":"JP Craig","year":"1997","unstructured":"Craig JP, Tomlinson A. Importance of the lipid layer in human tear film stability and evaporation. Optom Vis Sci. 1997;74:8\u201313.","journal-title":"Optom Vis Sci"},{"key":"2241_CR3","first-page":"522","volume":"20","author":"N Nicolaides","year":"1981","unstructured":"Nicolaides N, Kaitaranta JK, Rawdah TN, Macy JI, Boswell FM, Smith RE. Meibomian gland studies: comparison of steer and human lipids. Investig Ophthalmol Vis Sci. 1981;20:522\u201336.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2241_CR4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","volume":"15","author":"AJ Bron","year":"2017","unstructured":"Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II Pathophysiology report. Ocul Surf. 2017;15:438\u2013510.","journal-title":"Ocul Surf"},{"key":"2241_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.05.033","author":"JS Wolffsohn","year":"2025","unstructured":"Wolffsohn JS, Benitez-Del-Castillo J, Loya-Garcia D, Inomata T, Iyar G, Liang L, et al. TFOS DEWS III: Diagnostic Methodology. Am J Ophthalmol. 2025;279:387-450.","journal-title":"Am J Ophthalmol"},{"key":"2241_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.05.040","author":"F Stapleton","year":"2025","unstructured":"Stapleton F, Argueso P, Asbell P, Azar D, Bosworth C, Chen W, et al. TFOS DEWS III: Digest. Am J Ophthalmol. 2025;279:451-553.","journal-title":"Am J Ophthalmol"},{"key":"2241_CR7","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1167\/iovs.10-6997b","volume":"52","author":"JD Nelson","year":"2011","unstructured":"Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011;52:1930\u20137.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2241_CR8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/bjophthalmol-2015-307415","volume":"100","author":"C Baudouin","year":"2016","unstructured":"Baudouin C, Messmer EM, Aragona P, Geerling G, Akova YA, Benitez-del-Castillo J, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100:300\u20136.","journal-title":"Br J Ophthalmol"},{"key":"2241_CR9","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00347-009-2044-8","volume":"106","author":"E Knop","year":"2009","unstructured":"Knop E, Knop N. Meibomian glands\u202f: part IV. Functional interactions in the pathogenesis of meibomian gland dysfunction (MGD). Ophthalmologe. 2009;106:980\u20137.","journal-title":"Ophthalmologe"},{"key":"2241_CR10","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/09273948.2021.1905856","volume":"29","author":"J Dietrich","year":"2021","unstructured":"Dietrich J, Garreis F, Paulsen F. Pathophysiology of meibomian glands\u2013an overview. Ocul Immunol Inflamm. 2021;29:803\u201310.","journal-title":"Ocul Immunol Inflamm"},{"key":"2241_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.17925\/EOR.2014.08.01.13","volume":"8","author":"E Viso","year":"2014","unstructured":"Viso E, Mill\u00e1n AC, Rodr\u00edguez-Ares MT. Rosacea-associated meibomian gland dysfunction\u2014an epidemiological perspective. Eur Ophthalmic Rev. 2014;8:13\u20136.","journal-title":"Eur Ophthalmic Rev"},{"key":"2241_CR12","volume":"54","author":"GJ Chader","year":"2013","unstructured":"Chader GJ, Taylor A. Preface: the aging eye: normal changes, age-related diseases, and sight-saving approaches. Invest Ophthalmol Vis Sci. 2013;54:ORSF1-4.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2241_CR13","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1167\/iovs.10-6997a","volume":"52","author":"KK Nichols","year":"2011","unstructured":"Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52:1922\u20139.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2241_CR14","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1007\/s10792-023-02721-2","volume":"43","author":"J Feng","year":"2023","unstructured":"Feng J, Wang J, Wu B, Shao Q, Zang Y, Cao K, et al. Association of meibomian gland morphology with orifice plugging and lid margin thickening in meibomian gland dysfunction patients. Int Ophthalmol. 2023;43:3207\u201318.","journal-title":"Int Ophthalmol"},{"key":"2241_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2024.102324","volume":"48","author":"MTM Wang","year":"2025","unstructured":"Wang MTM, Power B, Xue AL, Kim JS, Craig JP. Diagnostic performance of qualitative and quantitative methods of meibomian gland dropout evaluation in dry eye disease: an investigator-masked, randomised crossover study. Cont Lens Anterior Eye. 2025;48:102324.","journal-title":"Contact Lens Anterior Eye"},{"key":"2241_CR16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jtos.2024.09.009","volume":"34","author":"MTM Wang","year":"2024","unstructured":"Wang MTM, Wolffsohn JS, Kim JS, Speakman S, Pritchard E, Power B, et al. Meibomian gland tortuosity, truncation, and dilation in paediatric dry eye disease: a multi-centre, investigator-masked, cross-sectional study. Ocul Surf. 2024;34:441\u20133.","journal-title":"Ocul Surf"},{"key":"2241_CR17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II Definition and classification report. Ocul Surf. 2017;15:276\u201383.","journal-title":"Ocul Surf"},{"key":"2241_CR18","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1167\/iovs.10-6997g","volume":"52","author":"G Geerling","year":"2011","unstructured":"Geerling G, Tauber J, Baudouin C, Goto E, Matsumoto Y, O\u2019Brien T, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52:2050\u201364.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2241_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.survophthal.2019.08.007","volume":"65","author":"S Sabeti","year":"2020","unstructured":"Sabeti S, Kheirkhah A, Yin J, Dana R. Management of meibomian gland dysfunction: a review. Surv Ophthalmol. 2020;65:205\u201317.","journal-title":"Surv Ophthalmol"},{"key":"2241_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/bmj.328.7430.39","volume":"328","author":"P Glasziou","year":"2004","unstructured":"Glasziou P, Vandenbroucke JP, Chalmers I. Assessing the quality of research. BMJ. 2004;328:39\u201341.","journal-title":"BMJ"},{"key":"2241_CR21","unstructured":"JBI Levels of Evidence. Joanna Briggs Institute 2013. https:\/\/jbi.global\/sites\/default\/files\/2019-05\/JBI-Levels-of-evidence_2014_0.pdf. Accessed 12 Sep 2025."},{"key":"2241_CR22","doi-asserted-by":"publisher","first-page":"4182787","DOI":"10.1155\/2023\/4182787","volume":"2023","author":"M Aly Zaky","year":"2023","unstructured":"Aly Zaky M, Galal Zaky A, Fayez Elsawy M, Fatehy Shehata K, Samy Abd Elaziz M. Efficacy of topical azithromycin versus systemic doxycycline in treatment of meibomian gland dysfunction. J Ophthalmol. 2023;2023:4182787.","journal-title":"J Ophthalmol"},{"key":"2241_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5935\/0004-2749.20200016","volume":"83","author":"FMX Andrade","year":"2020","unstructured":"Andrade FMX, Picosse FR, Cunha LPD, Valente CM, Bezerra FM, Miot H, et al. Ocular surface changes in the treatment of rosacea: comparison between low-dose oral isotretinoin and doxycycline. Arq Bras Oftalmol. 2020;83:109\u201312.","journal-title":"Arq Bras Oftalmol"},{"key":"2241_CR24","first-page":"544","volume":"8","author":"A Arman","year":"2015","unstructured":"Arman A, Demirseren DD, Takmaz T. Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline. Int J Ophthalmol. 2015;8:544\u20139.","journal-title":"Int J Ophthalmol"},{"key":"2241_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.71152\/ajms.v16i4.4441","volume":"16","author":"S Dhakal","year":"2025","unstructured":"Dhakal S, Shrestha S, Karki P, Dhakal S. Oral azithromycin versus doxycycline in meibomian gland dysfunction: a hospital-based study at Nepal Eye Hospital. Asian J Med Sci. 2025;16:84\u20139.","journal-title":"Asian J Med Sci"},{"key":"2241_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/OPTH.S150433","volume":"12","author":"KB Hagen","year":"2018","unstructured":"Hagen KB, Bedi R, Blackie CA, Christenson-Akagi KJ. Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. Clin Ophthalmol. 2018;12:161\u20138.","journal-title":"Clin Ophthalmol"},{"key":"2241_CR27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.21608\/ejhm.2019.23195","volume":"74","author":"AH Hamed","year":"2019","unstructured":"Hamed AH, Bayoumi HM, Morad MMM. Comparative study between usage of topical azithromycin versus conventional therapy in treatment of posterior blepharitis causing dry eye. Egypt J Hosp Med. 2019;74:543\u20139.","journal-title":"Egypt J Hosp Med"},{"key":"2241_CR28","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1177\/112067210901900504","volume":"19","author":"A Iovieno","year":"2009","unstructured":"Iovieno A, Lambiase A, Micera A, Stampachiacchiere B, Sgrulletta R, Bonini S. In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis. Eur J Ophthalmol. 2009;19:708\u201316.","journal-title":"Eur J Ophthalmol"},{"key":"2241_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/bjophthalmol-2014-305410","volume":"99","author":"MB Kashkouli","year":"2015","unstructured":"Kashkouli MB, Fazel AJ, Kiavash V, Nojomi M, Ghiasian L. Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomised double-masked open-label clinical trial. Br J Ophthalmol. 2015;99:199\u2013204.","journal-title":"Br J Ophthalmol"},{"key":"2241_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3126\/nepjoph.v16i1.46383","volume":"16","author":"A Koirala","year":"2024","unstructured":"Koirala A, Bhattarai S, Shah S, Shrestha BG, Lavaju P. Efficacy of oral azithromycin versus doxycycline in treatment of meibomian gland dysfunction. Nepal J Ophthalmol. 2024;16:13\u20139.","journal-title":"Nepal J Ophthalmol"},{"key":"2241_CR31","first-page":"107","volume":"3","author":"R Kothari","year":"2017","unstructured":"Kothari R, Patel D, Patel N, Patel A, Rajput T. Observational comparative study to evaluate the efficacy of oral azithromycin and oral doxycycline in management of meibomian gland dysfunction. Indian J Clin Exp Ophthalmol. 2017;3:107\u201311.","journal-title":"Indian J Clin Exp Ophthalmol"},{"key":"2241_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3109\/09273948.2013.801991","volume":"21","author":"F Mantelli","year":"2013","unstructured":"Mantelli F, Di Zazzo A, Sacchetti M, Dianzani C, Lambiase A, Bonini S. Topical azithromycin as a novel treatment for ocular rosacea. Ocul Immunol Inflamm. 2013;21:371\u20137.","journal-title":"Ocul Immunol Inflamm"},{"key":"2241_CR33","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00417-019-04322-1","volume":"257","author":"V Satitpitakul","year":"2019","unstructured":"Satitpitakul V, Ratanawongphaibul K, Kasetsuwan N, Reinprayoon U. Efficacy of azithromycin 1.5% eyedrops vs oral doxycycline in meibomian gland dysfunction: a randomized trial. Graefes Arch Clin Exp Ophthalmol. 2019;257:1289\u201394.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2241_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1089\/jop.2022.0186","volume":"39","author":"A Schlatter","year":"2023","unstructured":"Schlatter A, Hommer N, Kallab M, Stegmann H, Zeller K, Palkovits S, et al. Effect of treatment with topical azithromycin or oral doxycycline on tear film thickness in patients with meibomian gland dysfunction: a randomized controlled trial. J Ocul Pharmacol Ther. 2023;39:371\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2241_CR35","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jamaophthalmol.2023.0302","volume":"141","author":"P Upaphong","year":"2023","unstructured":"Upaphong P, Tangmonkongvoragul C, Phinyo P. Pulsed oral azithromycin vs 6-week oral doxycycline for moderate to severe meibomian gland dysfunction: a randomized clinical trial. JAMA Ophthalmol. 2023;141:423\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"2241_CR36","doi-asserted-by":"publisher","first-page":"S312","DOI":"10.51253\/pafmj.v73i3.8815","volume":"73","author":"W Yousuf","year":"2023","unstructured":"Yousuf W, Humayun F, Janjua TA, Khan TA, Sarfraz MH, Mehboob MA. Comparison between efficacy and safety of oral azithromycin (250mg) vs oral doxycycline (100mg) in treatment of meibomian gland dysfunction (MGD). Pak Armed Forces Med J. 2023;73:S312\u20135.","journal-title":"Pak Armed Forces Med J."},{"key":"2241_CR37","first-page":"1016","volume":"9","author":"M Zandian","year":"2016","unstructured":"Zandian M, Rahimian N, Soheilifar S. Comparison of therapeutic effects of topical azithromycin solution and systemic doxycycline on posterior blepharitis. Int J Ophthalmol. 2016;9:1016\u20139.","journal-title":"Int J Ophthalmol"},{"key":"2241_CR38","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1468-3083.2009.03132.x","volume":"23","author":"O Bakar","year":"2009","unstructured":"Bakar O, Demircay Z, Toker E, Cakir S. Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. J Eur Acad Dermatol Venereol. 2009;23:544\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2241_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/ICO.0000000000002233","volume":"39","author":"E Ciloglu","year":"2020","unstructured":"Ciloglu E, Ozcan AA, Incekalan T, Unal F. The role of topical azithromycin in the treatment of meibomian gland dysfunction. Cornea. 2020;39:321\u20134.","journal-title":"Cornea"},{"key":"2241_CR40","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1097\/ICO.0b013e318207fc42","volume":"30","author":"TZ Igami","year":"2011","unstructured":"Igami TZ, Holzchuh R, Osaki TH, Santo RM, Kara-Jose N, Hida RY. Oral azithromycin for treatment of posterior blepharitis. Cornea. 2011;30:1145\u20139.","journal-title":"Cornea"},{"key":"2241_CR41","doi-asserted-by":"publisher","first-page":"102","DOI":"10.4103\/ojo.ojo_114_22","volume":"17","author":"SK Kodavoor","year":"2024","unstructured":"Kodavoor SK, Jayashri M, Patekar KB, Ramamurthy S, Sachdev G. Comparison of a single-dose vectored thermal pulsation procedure with 5-day course of daily oral azithromycin for meibomian gland dysfunction. Oman J Ophthalmol. 2024;17:102\u20137.","journal-title":"Oman J Ophthalmol"},{"key":"2241_CR42","first-page":"123","volume":"5","author":"A Shaarawy","year":"2020","unstructured":"Shaarawy A, Shalaby O, Sewilam M. The clinical efficacy of topical and systemic azithromycin treatment for posterior blepharitis. Benha J Appl Sci. 2020;5:123\u20139.","journal-title":"Benha J Appl Sci"},{"key":"2241_CR43","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1089\/jop.2017.0095","volume":"34","author":"E Yildiz","year":"2018","unstructured":"Yildiz E, Yenerel NM, Turan-Yardimci A, Erkan M, Gunes P. Comparison of the clinical efficacy of topical and systemic azithromycin treatment for posterior blepharitis. J Ocul Pharmacol Ther. 2018;34:365\u201372.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2241_CR44","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/bjo.2006.091579","volume":"90","author":"JD Aronowicz","year":"2006","unstructured":"Aronowicz JD, Shine WE, Oral D, Vargas JM, McCulley JP. Short term oral minocycline treatment of meibomianitis. Br J Ophthalmol. 2006;90:856\u201360.","journal-title":"Br J Ophthalmol"},{"key":"2241_CR45","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ajo.2012.06.009","volume":"154","author":"H Lee","year":"2012","unstructured":"Lee H, Min K, Kim EK, Kim TI. Minocycline controls clinical outcomes and inflammatory cytokines in moderate and severe meibomian gland dysfunction. Am J Ophthalmol. 2012;154:949\u201357 (e1).","journal-title":"Am J Ophthalmol"},{"key":"2241_CR46","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/bjo.2007.133900","volume":"92","author":"M Souchier","year":"2008","unstructured":"Souchier M, Joffre C, Gregoire S, Bretillon L, Muselier A, Acar N, et al. Changes in meibomian fatty acids and clinical signs in patients with meibomian gland dysfunction after minocycline treatment. Br J Ophthalmol. 2008;92:819\u201322.","journal-title":"Br J Ophthalmol"},{"key":"2241_CR47","first-page":"471","volume":"1","author":"NE Holmes","year":"2009","unstructured":"Holmes NE, Charles PGP. Safety and efficacy review of doxycycline. Clin Med Insights. 2009;1:471\u201382.","journal-title":"Clin Med Insights"},{"key":"2241_CR48","doi-asserted-by":"publisher","first-page":"750","DOI":"10.2165\/00003495-199244050-00007","volume":"44","author":"DH Peters","year":"1992","unstructured":"Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1992;44:750\u201399.","journal-title":"Drugs"},{"key":"2241_CR49","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1365-4632.2008.03445.x","volume":"47","author":"M Akhyani","year":"2008","unstructured":"Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol. 2008;47:284\u20138.","journal-title":"Int J Dermatol"},{"key":"2241_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ICO.0b013e3181da5778","volume":"30","author":"E Viso","year":"2011","unstructured":"Viso E, Gude F, Rodriguez-Ares MT. The association of meibomian gland dysfunction and other common ocular diseases with dry eye: a population-based study in Spain. Cornea. 2011;30:1\u20136.","journal-title":"Cornea"},{"key":"2241_CR51","doi-asserted-by":"publisher","first-page":"466","DOI":"10.5935\/0004-2749.20180093","volume":"81","author":"B Bilgin","year":"2018","unstructured":"Bilgin B, Karadag AS. Effects of combined oral doxycycline and topical cyclosporine treatment on ocular signs, symptoms, and tear film parameters in rosacea patients. Arq Bras Oftalmol. 2018;81:466\u201370.","journal-title":"Arq Bras Oftalmol"},{"key":"2241_CR52","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s00417-005-0212-3","volume":"244","author":"M Maatta","year":"2006","unstructured":"Maatta M, Kari O, Tervahartiala T, Peltonen S, Kari M, Saari M, et al. Tear fluid levels of MMP-8 are elevated in ocular rosacea\u2013treatment effect of oral doxycycline. Graefes Arch Clin Exp Ophthalmol. 2006;244:957\u201362.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2241_CR53","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/329418","volume":"2015","author":"R Di Caprio","year":"2015","unstructured":"Di Caprio R, Lembo S, Di Costanzo L, Balato A, Monfrecola G. Anti-inflammatory properties of low and high doxycycline doses: an in vitro study. Mediat Inflamm. 2015;2015:329418.","journal-title":"Mediat Inflamm"},{"key":"2241_CR54","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1345\/aph.1E282","volume":"39","author":"SA Voils","year":"2005","unstructured":"Voils SA, Evans ME, Lane MT, Schosser RH, Rapp RP. Use of macrolides and tetracyclines for chronic inflammatory diseases. Ann Pharmacother. 2005;39:86\u201394.","journal-title":"Ann Pharmacother"},{"key":"2241_CR55","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1001\/jamaophthalmol.2015.2326","volume":"133","author":"L Zhang","year":"2015","unstructured":"Zhang L, Su Z, Zhang Z, Lin J, Li DQ, Pflugfelder SC. Effects of azithromycin on gene expression profiles of proinflammatory and anti-inflammatory mediators in the eyelid margin and conjunctiva of patients with meibomian gland disease. JAMA Ophthalmol. 2015;133:1117\u201323.","journal-title":"JAMA Ophthalmol"},{"key":"2241_CR56","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0014-4835(03)00005-8","volume":"76","author":"WE Shine","year":"2003","unstructured":"Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res. 2003;76:417\u201320.","journal-title":"Exp Eye Res"},{"key":"2241_CR57","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1001\/archopht.116.12.1625","volume":"116","author":"KF Tabbara","year":"1998","unstructured":"Tabbara KF, al-Kharashi SA, al-Mansouri SM, al-Omar OM, Cooper H, el-Asrar AM, et al. Ocular levels of azithromycin. Arch Ophthalmol. 1998;116:1625\u20138.","journal-title":"Arch Ophthalmol"},{"key":"2241_CR58","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3341\/kjo.2005.19.4.258","volume":"19","author":"SE Yoo","year":"2005","unstructured":"Yoo SE, Lee DC, Chang MH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. Korean J Ophthalmol. 2005;19:258\u201363.","journal-title":"Korean J Ophthalmol"},{"key":"2241_CR59","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1365-4632.2004.01958.x","volume":"43","author":"O Bakar","year":"2004","unstructured":"Bakar O, Demircay Z, Gurbuz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol. 2004;43:151\u20134.","journal-title":"Int J Dermatol"},{"key":"2241_CR60","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1365-2230.2005.01769.x","volume":"30","author":"S Kus","year":"2005","unstructured":"Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol. 2005;30:215\u201320.","journal-title":"Clin Exp Dermatol"},{"key":"2241_CR61","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.ajo.2006.06.047","volume":"142","author":"A Cetinkaya","year":"2006","unstructured":"Cetinkaya A, Akova YA. Pediatric ocular acne rosacea: long-term treatment with systemic antibiotics. Am J Ophthalmol. 2006;142:816\u201321.","journal-title":"Am J Ophthalmol"},{"key":"2241_CR62","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/ICL.0000000000000729","volume":"47","author":"R Arita","year":"2021","unstructured":"Arita R, Fukuoka S. Efficacy of azithromycin eyedrops for individuals with meibomian gland dysfunction-associated posterior blepharitis. Eye Contact Lens. 2021;47:54\u20139.","journal-title":"Eye Contact Lens"},{"key":"2241_CR63","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1590\/S0004-27492012000300006","volume":"75","author":"A Fadlallah","year":"2012","unstructured":"Fadlallah A, Rami HE, Fahd D, Dunia I, Bejjani R, Chlela E, et al. Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis. Arq Bras Oftalmol. 2012;75:178\u201382.","journal-title":"Arq Bras Oftalmol"},{"key":"2241_CR64","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/ICO.0b013e3181cda38f","volume":"29","author":"GN Foulks","year":"2010","unstructured":"Foulks GN, Borchman D, Yappert M, Kim SH, McKay JW. Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations. Cornea. 2010;29:781\u20138.","journal-title":"Cornea"},{"key":"2241_CR65","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1097\/ICO.0b013e3181ca38a0","volume":"29","author":"RM Haque","year":"2010","unstructured":"Haque RM, Torkildsen GL, Brubaker K, Zink RC, Kowalski RP, Mah FS, et al. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea. 2010;29:871\u20137.","journal-title":"Cornea"},{"key":"2241_CR66","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/opo.13330","volume":"44","author":"I Jarvis","year":"2024","unstructured":"Jarvis I, McCullough S, Jarvis J. The topical azithromycin meibomian gland dysfunction survey: the effect of topical azithromycin on signs and symptoms of meibomian gland dysfunction. Ophthalmic Physiol Opt. 2024;44:910\u20136.","journal-title":"Ophthalmic Physiol Opt"},{"key":"2241_CR67","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s12325-008-0096-9","volume":"25","author":"J Luchs","year":"2008","unstructured":"Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther. 2008;25:858\u201370.","journal-title":"Adv Ther"},{"key":"2241_CR68","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1444-0938.2010.00540.x","volume":"94","author":"DL Opitz","year":"2011","unstructured":"Opitz DL, Tyler KF. Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. Clin Exp Optom. 2011;94:200\u20136.","journal-title":"Clin Exp Optom"},{"key":"2241_CR69","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/ICO.0b013e318254205f","volume":"32","author":"GN Foulks","year":"2013","unstructured":"Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea. 2013;32:44\u201353.","journal-title":"Cornea"},{"key":"2241_CR70","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jtos.2020.12.006","volume":"20","author":"JP Craig","year":"2021","unstructured":"Craig JP, Muntz A, Wang MTM, Luensmann D, Tan J, Trave Huarte S, et al. Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: a six-month multicentre, double-masked randomised controlled trial. Ocul Surf. 2021;20:62\u20139.","journal-title":"Ocul Surf"},{"key":"2241_CR71","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4187\/respcare.06314","volume":"63","author":"DM Williams","year":"2018","unstructured":"Williams DM. Clinical pharmacology of corticosteroids. Respir Care. 2018;63:655\u201370.","journal-title":"Respir Care"},{"key":"2241_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158017","volume":"11","author":"AK Waljee","year":"2016","unstructured":"Waljee AK, Wiitala WL, Govani S, Stidham R, Saini S, Hou J, et al. Corticosteroid use and complications in a US inflammatory bowel disease cohort. PLoS ONE. 2016;11:e0158017.","journal-title":"PLoS ONE"},{"key":"2241_CR73","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","volume":"201","author":"ER Bleecker","year":"2020","unstructured":"Bleecker ER, Menzies-Gow AN, Price DB, Bourdin A, Sweet S, Martin AL, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201:276\u201393.","journal-title":"Am J Respir Crit Care Med"},{"key":"2241_CR74","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s13346-020-00843-z","volume":"11","author":"SA Gaballa","year":"2021","unstructured":"Gaballa SA, Kompella UB, Elgarhy O, Alqahtani AM, Pierscionek B, Alany RG, et al. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res. 2021;11:866\u201393.","journal-title":"Drug Deliv Transl Res"},{"key":"2241_CR75","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","volume":"15","author":"M Oray","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15:457\u201365.","journal-title":"Expert Opin Drug Saf"},{"key":"2241_CR76","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/bjo.2008.154906","volume":"93","author":"MA Awan","year":"2009","unstructured":"Awan MA, Agarwal PK, Watson DG, McGhee CN, Dutton GN. Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance. Br J Ophthalmol. 2009;93:708\u201313.","journal-title":"Br J Ophthalmol"},{"key":"2241_CR77","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.sjopt.2018.06.001","volume":"32","author":"TM Othman","year":"2018","unstructured":"Othman TM, Mousa A, Gikandi PW, AbdelMabod M, Abdelrahman AM. Efficacy and safety of using topical cyclosporine A for treatment of moderate to severe dry eye disease. Saudi J Ophthalmol. 2018;32:217\u201321.","journal-title":"Saudi J Ophthalmol"},{"key":"2241_CR78","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Craig JP, Markoulli M, Karpecki P, Akpek EK, Basu S, et al. TFOS DEWS III: Management and Therapy. Am J Ophthalmol. 2025;279:289\u2013386.","journal-title":"Ocul Surf"},{"key":"2241_CR79","volume":"59","author":"T Yamaguchi","year":"2018","unstructured":"Yamaguchi T. Inflammatory response in dry eye. Investig Ophthalmol Vis Sci. 2018;59:DES192-DES9.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2241_CR80","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/eye.2017.213","volume":"32","author":"JS Ko","year":"2018","unstructured":"Ko JS, Seo Y, Chae MK, Jang SY, Yoon JS. Effect of topical loteprednol etabonate with lid hygiene on tear cytokines and meibomian gland dysfunction in prosthetic eye wearers. Eye (Lond). 2018;32:439\u201345.","journal-title":"Eye (Lond)"},{"issue":"1172\u201383","key":"2241_CR81","volume":"158","author":"H Lee","year":"2014","unstructured":"Lee H, Chung B, Kim KS, Seo KY, Choi BJ, Kim TI. Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial. Am J Ophthalmol. 2014;158(1172\u201383):e1.","journal-title":"Am J Ophthalmol"},{"key":"2241_CR82","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/ICO.0000000000000777","volume":"35","author":"X Ma","year":"2016","unstructured":"Ma X, Lu Y. Efficacy of intraductal meibomian gland probing on tear function in patients with obstructive meibomian gland dysfunction. Cornea. 2016;35:725\u201330.","journal-title":"Cornea"},{"key":"2241_CR83","doi-asserted-by":"publisher","first-page":"6037401","DOI":"10.1155\/2022\/6037401","volume":"2022","author":"YS Choi","year":"2022","unstructured":"Choi YS, Paik HJ, Kim DH. Comparison of consecutive therapeutic effects of nanoemulsion and emulsion cyclosporin in dry eye patients after short-term treatment with topical fluorometholone. J Ophthalmol. 2022;2022:6037401.","journal-title":"J Ophthalmol"},{"key":"2241_CR84","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/13102818.2019.1656107","volume":"33","author":"X Guo","year":"2019","unstructured":"Guo X, Li A, Fan Y, Yu Y, Guo W, Jie Y. Combined use of 0.1% fluorometholone and meibomian gland expression improves symptoms of moderate and severe dry eye disease, even in patients with systemic immune disease. Biotechnol Biotechnol Equip. 2019;33:1237\u201343.","journal-title":"Biotechnol Biotechnol Equip"},{"key":"2241_CR85","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","volume":"130","author":"DA Jabs","year":"2000","unstructured":"Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492\u2013513.","journal-title":"Am J Ophthalmol"},{"key":"2241_CR86","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.18240\/ijo.2019.11.07","volume":"12","author":"YF Gao","year":"2019","unstructured":"Gao YF, Liu RJ, Li YX, Huang C, Liu YY, Hu CX, et al. Comparison of anti-inflammatory effects of intense pulsed light with tobramycin\/dexamethasone plus warm compress on dry eye associated meibomian gland dysfunction. Int J Ophthalmol. 2019;12:1708\u201313.","journal-title":"Int J Ophthalmol"},{"key":"2241_CR87","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1177\/11206721241293175","volume":"35","author":"GW Oliverio","year":"2025","unstructured":"Oliverio GW, Inferrera L, Postorino EI, Palino P, Aragona P. The efficacy of a netilmicin\/dexamethasone gel combination in the treatment of posterior blepharitis in moderate-severe dry eye patients. Eur J Ophthalmol. 2025;35:878\u201383.","journal-title":"Eur J Ophthalmol"},{"key":"2241_CR88","doi-asserted-by":"publisher","first-page":"2737968","DOI":"10.1155\/2019\/2737968","volume":"2019","author":"P Song","year":"2019","unstructured":"Song P, Sun Z, Ren S, Yang K, Deng G, Zeng Q, et al. Preoperative management of MGD alleviates the aggravation of MGD and dry eye induced by cataract surgery: a prospective, randomized clinical trial. Biomed Res Int. 2019;2019:2737968.","journal-title":"Biomed Res Int"},{"key":"2241_CR89","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/jop.2006.22.47","volume":"22","author":"M Rubin","year":"2006","unstructured":"Rubin M, Rao SN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther. 2006;22:47\u201353.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2241_CR90","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3341\/kjo.2009.23.2.65","volume":"23","author":"YK Cho","year":"2009","unstructured":"Cho YK, Kim MS. Dry eye after cataract surgery and associated intraoperative risk factors. Korean J Ophthalmol. 2009;23:65\u201373.","journal-title":"Korean J Ophthalmol"},{"key":"2241_CR91","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.2147\/OPTH.S257541","volume":"14","author":"A Rapisarda","year":"2020","unstructured":"Rapisarda A, Arpa P, Fantaguzzi PM, Faraldi F, Ratiglia R, Rizzo S, et al. Dexamethasone\/netilmicin eye drops and eye gel for the treatment of ocular inflammation after micro-incisional vitreoretinal surgery. Clin Ophthalmol. 2020;14:3297\u2013303.","journal-title":"Clin Ophthalmol"},{"key":"2241_CR92","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.18240\/ijo.2022.12.05","volume":"15","author":"YJ Jo","year":"2022","unstructured":"Jo YJ, Lee JE, Lee JS. Clinical efficacy of 0.05% cyclosporine nano-emulsion in the treatment of dry eye syndrome associated with meibomian gland dysfunction. Int J Ophthalmol. 2022;15:1924\u201331.","journal-title":"Int J Ophthalmol"},{"key":"2241_CR93","doi-asserted-by":"publisher","first-page":"2","DOI":"10.71177\/jcco.v2i01.53","volume":"2","author":"B Khan","year":"2024","unstructured":"Khan B, Ahmad A, Rasul J, Farhan M, Rehman H. Efficacy of tacrolimus 0.03% ointment in resistant meibomian gland dysfunction. J Clin Comm Ophthalmol. 2024;2:2\u20136.","journal-title":"J Clin Comm Ophthalmol"},{"key":"2241_CR94","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/01.ico.0000176611.88579.0a","volume":"25","author":"HD Perry","year":"2006","unstructured":"Perry HD, Doshi-Carnevale S, Donnenfeld ED, Solomon R, Biser SA, Bloom AH. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006;25:171\u20135.","journal-title":"Cornea"},{"key":"2241_CR95","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1097\/ICO.0b013e31823cc098","volume":"31","author":"P Prabhasawat","year":"2012","unstructured":"Prabhasawat P, Tesavibul N, Mahawong W. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea. 2012;31:1386\u201393.","journal-title":"Cornea"},{"key":"2241_CR96","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s10384-022-00906-3","volume":"66","author":"JW Rhim","year":"2022","unstructured":"Rhim JW, Eom Y, Yoon EG, Park SY, Choi Y, Song JS, et al. Efficacy of a 0.05% cyclosporine a topical nanoemulsion in dry eyes with obstructive meibomian gland dysfunction. Jpn J Ophthalmol. 2022;66:254\u201363.","journal-title":"Jpn J Ophthalmol"},{"key":"2241_CR97","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1080\/02713683.2017.1339805","volume":"42","author":"FE Sakassegawa-Naves","year":"2017","unstructured":"Sakassegawa-Naves FE, Ricci HMM, Moscovici BK, Miyamoto DA, Chiacchio BB, Holzchuh R, et al. Tacrolimus ointment for refractory posterior blepharitis. Curr Eye Res. 2017;42:1440\u20134.","journal-title":"Curr Eye Res"},{"key":"2241_CR98","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.2147\/OPTH.S279051","volume":"14","author":"LM Periman","year":"2020","unstructured":"Periman LM, Mah FS, Karpecki PM. A review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and recent formulation developments. Clin Ophthalmol. 2020;14:4187\u2013200.","journal-title":"Clin Ophthalmol"},{"key":"2241_CR99","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1159\/000080937","volume":"218","author":"E Bertelmann","year":"2004","unstructured":"Bertelmann E, Pleyer U. Immunomodulatory therapy in ophthalmology\u2014is there a place for topical application? Ophthalmologica. 2004;218:359\u201367.","journal-title":"Ophthalmologica"},{"key":"2241_CR100","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0168-3659(98)00150-3","volume":"57","author":"H Yura","year":"1999","unstructured":"Yura H, Yoshimura N, Hamashima T, Akamatsu K, Nishikawa M, Takakura Y, et al. Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate. J Control Release. 1999;57:87\u201399.","journal-title":"J Control Release"},{"key":"2241_CR101","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/00007890-198902000-00035","volume":"47","author":"N Yoshimura","year":"1989","unstructured":"Yoshimura N, Matsui S, Hamashima T, Oka T. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. Transplantation. 1989;47:356\u20139.","journal-title":"Transplantation"},{"key":"2241_CR102","unstructured":"Zeevi A, Duquesnoy R, Eiras G, Rabinowich H, Todo S, Makowka L, Starzl T. Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc NIH Public Access; 1987. p. 40."},{"key":"2241_CR103","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","volume":"16","author":"JCA Broen","year":"2020","unstructured":"Broen JCA, van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat Rev Rheumatol. 2020;16:167\u201378.","journal-title":"Nat Rev Rheumatol"},{"key":"2241_CR104","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/ICO.0000000000002235","volume":"39","author":"J Tauber","year":"2020","unstructured":"Tauber J. A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea. 2020;39:403\u20137.","journal-title":"Cornea"},{"key":"2241_CR105","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2147\/OPTH.S196593","volume":"13","author":"JS Pepose","year":"2019","unstructured":"Pepose JS, Qazi MA, Devries DK. Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity. Clin Ophthalmol. 2019;13:571\u20139.","journal-title":"Clin Ophthalmol"},{"issue":"Suppl 1","key":"2241_CR106","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/ICL.0000000000000601","volume":"46","author":"AY Tong","year":"2020","unstructured":"Tong AY, Passi SF, Gupta PK. Clinical outcomes of lifitegrast 5% ophthalmic solution in the treatment of dry eye disease. Eye Contact Lens. 2020;46(Suppl 1):S20\u20134.","journal-title":"Eye Contact Lens"},{"key":"2241_CR107","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/ICO.0000000000003266","volume":"43","author":"EVT Locatelli","year":"2024","unstructured":"Locatelli EVT, Acuna KA, Betz J, Tovar AA, Galor A. Comparison of subjective responses to cyclosporine 0.05% versus lifitegrast 5.0% in individuals with dry eye disease. Cornea. 2024;43:88\u201394.","journal-title":"Cornea"},{"key":"2241_CR108","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000076887","volume":"36","author":"T Murakami","year":"2004","unstructured":"Murakami T, Fujihara T, Horibe Y, Nakamura M. Diquafosol elicits increases in net Cl- transport through P2Y2 receptor stimulation in rabbit conjunctiva. Ophthalmic Res. 2004;36:89\u201393.","journal-title":"Ophthalmic Res"},{"key":"2241_CR109","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s12325-012-0033-9","volume":"29","author":"M Nakamura","year":"2012","unstructured":"Nakamura M, Imanaka T, Sakamoto A. Diquafosol ophthalmic solution for dry eye treatment. Adv Ther. 2012;29:579\u201389.","journal-title":"Adv Ther"},{"key":"2241_CR110","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.2147\/OPTH.S148167","volume":"11","author":"S Amano","year":"2017","unstructured":"Amano S, Inoue K. Effect of topical 3% diquafosol sodium on eyes with dry eye disease and meibomian gland dysfunction. Clin Ophthalmol. 2017;11:1677\u201382.","journal-title":"Clin Ophthalmol"},{"key":"2241_CR111","doi-asserted-by":"crossref","unstructured":"Dong Y, Li Z, Chen L. Comparative efficacy of 3% diquafosol sodium eye drops in dry eye patients across age groups: a propensity score-matched longitudinal study. 2024.","DOI":"10.21203\/rs.3.rs-4827759\/v1"},{"key":"2241_CR112","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jtos.2017.03.005","volume":"15","author":"S Fukuoka","year":"2017","unstructured":"Fukuoka S, Arita R. Increase in tear film lipid layer thickness after instillation of 3% diquafosol ophthalmic solution in healthy human eyes. Ocul Surf. 2017;15:730\u20135.","journal-title":"Ocul Surf"},{"key":"2241_CR113","doi-asserted-by":"publisher","first-page":"9091","DOI":"10.1038\/s41598-019-45475-7","volume":"9","author":"S Fukuoka","year":"2019","unstructured":"Fukuoka S, Arita R. Tear film lipid layer increase after diquafosol instillation in dry eye patients with meibomian gland dysfunction: a randomized clinical study. Sci Rep. 2019;9:9091.","journal-title":"Sci Rep"},{"key":"2241_CR114","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12886-020-01550-6","volume":"20","author":"Y Guo","year":"2020","unstructured":"Guo Y, Ha JY, Piao HL, Sung MS, Park SW. The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study. BMC Ophthalmol. 2020;20:277.","journal-title":"BMC Ophthalmol"},{"key":"2241_CR115","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1038\/s41598-024-63784-4","volume":"14","author":"Y Jin","year":"2024","unstructured":"Jin Y, Seo KY, Kim SW. Comparing two mucin secretagogues for the treatment of dry eye disease: a prospective randomized crossover trial. Sci Rep. 2024;14:13306.","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"2241_CR116","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1007\/s10620-005-2800-9","volume":"50","author":"T Arakawa","year":"2005","unstructured":"Arakawa T, Higuchi K, Fujiwara Y, Watanabe T, Tominaga K, Sasaki E, et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50(Suppl 1):S3\u201311.","journal-title":"Dig Dis Sci"},{"key":"2241_CR117","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1016\/j.ophtha.2012.06.052","volume":"119","author":"S Kinoshita","year":"2012","unstructured":"Kinoshita S, Awamura S, Oshiden K, Nakamichi N, Suzuki H, Yokoi N. Rebamipide ophthalmic suspension phase IISG. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology. 2012;119:2471\u20138.","journal-title":"Ophthalmology"},{"key":"2241_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-015-0040-0","volume":"15","author":"K Ueda","year":"2015","unstructured":"Ueda K, Matsumiya W, Otsuka K, Maeda Y, Nagai T, Nakamura M. Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye. BMC Ophthalmol. 2015;15:58.","journal-title":"BMC Ophthalmol"},{"key":"2241_CR119","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-023-03004-1","volume":"23","author":"Y Eom","year":"2023","unstructured":"Eom Y, Chung SH, Chung TY, Kim JY, Choi CY, Yoon KC, et al. Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: a multicenter randomized trial. BMC Ophthalmol. 2023;23:343.","journal-title":"BMC Ophthalmol"},{"key":"2241_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041211","volume":"15","author":"C Tsagogiorgas","year":"2023","unstructured":"Tsagogiorgas C, Otto M. Semifluorinated alkanes as new drug carriers\u2014an overview of potential medical and clinical applications. Pharmaceutics. 2023;15:1211.","journal-title":"Pharmaceutics"},{"key":"2241_CR121","doi-asserted-by":"publisher","first-page":"S251","DOI":"10.37765\/ajmc.2023.89464","volume":"29","author":"JD Sheppard","year":"2023","unstructured":"Sheppard JD, Evans DG, Protzko EE. A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution. Am J Manag Care. 2023;29:S251\u20139.","journal-title":"Am J Manag Care"},{"key":"2241_CR122","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40265-024-02016-5","volume":"84","author":"A Zhuang-Yan","year":"2024","unstructured":"Zhuang-Yan A, Syed YY. Perfluorohexyloctane ophthalmic solution: a review in dry eye disease. Drugs. 2024;84:441\u20138.","journal-title":"Drugs"},{"key":"2241_CR123","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jtos.2023.10.001","volume":"30","author":"A Ballesteros-Sanchez","year":"2023","unstructured":"Ballesteros-Sanchez A, De-Hita-Cantalejo C, Sanchez-Gonzalez MC, Jansone-Langine Z, de Sotomayor MA, Culig J, et al. Perfluorohexyloctane in dry eye disease: a systematic review of its efficacy and safety as a novel therapeutic agent. Ocul Surf. 2023;30:254\u201362.","journal-title":"Ocul Surf"},{"key":"2241_CR124","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00417-022-05778-4","volume":"261","author":"AR Carreira","year":"2023","unstructured":"Carreira AR, Rodrigues-Barros S, Silva JC, de Almeida MF, Machado I, Cardoso JN, et al. Tobacco effects on ocular surface, meibomian glands, and corneal epithelium and the benefits of treatment with a lipid-based lubricant. Graefes Arch Clin Exp Ophthalmol. 2023;261:171\u201384.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2241_CR125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279977","volume":"18","author":"KJ Habbe","year":"2023","unstructured":"Habbe KJ, Frings A, Saad A, Geerling G. The influence of a mineral oil cationic nanoemulsion or perfluorohexyloctane on the tear film lipid layer and higher order aberrations. PLoS\u00a0One. 2023;18:e0279977.","journal-title":"PLoS\u00a0One"},{"key":"2241_CR126","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1089\/jop.2019.0092","volume":"36","author":"D Schmidl","year":"2020","unstructured":"Schmidl D, Bata AM, Szegedi S, AranhaDosSantos V, Stegmann H, Fondi K, et al. Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2020;36:154\u201361.","journal-title":"J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther"},{"key":"2241_CR127","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1089\/jop.2015.0048","volume":"31","author":"P Steven","year":"2015","unstructured":"Steven P, Scherer D, Krosser S, Beckert M, Cursiefen C, Kaercher T. Semifluorinated alkane eye drops for treatment of dry eye disease\u2013a prospective, multicenter noninterventional study. J Ocul Pharmacol Ther. 2015;31:498\u2013503.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2241_CR128","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1089\/jop.2017.0042","volume":"33","author":"P Steven","year":"2017","unstructured":"Steven P, Augustin AJ, Geerling G, Kaercher T, Kretz F, Kunert K, et al. Semifluorinated alkane eye drops for treatment of dry eye disease due to meibomian gland disease. J Ocul Pharmacol Ther. 2017;33:678\u201385.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2241_CR129","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jamaophthalmol.2023.0270","volume":"141","author":"L Tian","year":"2023","unstructured":"Tian L, Gao Z, Zhu L, Shi X, Zhao S, Gu H, et al. Perfluorohexyloctane eye drops for dry eye disease associated with meibomian gland dysfunction in Chinese patients: a randomized clinical trial. JAMA Ophthalmol. 2023;141:385\u201392.","journal-title":"JAMA Ophthalmol"},{"key":"2241_CR130","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1089\/jop.2021.0102","volume":"38","author":"C Jacobi","year":"2022","unstructured":"Jacobi C, Angstmann-Mehr S, Lange A, Kaercher T. A water-free omega-3 fatty acid eye drop formulation for the treatment of evaporative dry eye disease: a prospective, multicenter noninterventional study. J Ocul Pharmacol Ther. 2022;38:348\u201353.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2241_CR131","doi-asserted-by":"publisher","first-page":"L1018","DOI":"10.1152\/ajplung.2000.278.5.L1018","volume":"278","author":"VV Obraztsov","year":"2000","unstructured":"Obraztsov VV, Neslund GG, Kornbrust ES, Flaim SF, Woods CM. In vitro cellular effects of perfluorochemicals correlate with their lipid solubility. Am J Physiol Lung Cell Molec Physiol. 2000;278:L1018\u201324.","journal-title":"Am J Physiol Lung Cell Molec Physiol"},{"key":"2241_CR132","doi-asserted-by":"crossref","unstructured":"Ishak K, Annuar MM, Ahmad N. Nano-delivery systems for nutraceutical application. Nanotechnol App Food. Elsevier; 2017. p. 179\u2013202.","DOI":"10.1016\/B978-0-12-811942-6.00009-1"},{"key":"2241_CR133","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3390\/foods10061358","volume":"10","author":"EN Ponnampalam","year":"2021","unstructured":"Ponnampalam EN, Sinclair AJ, Holman BWB. The sources, synthesis and biological actions of omega-3 and omega-6 fatty acids in red meat: an overview. Foods. 2021;10:1358.","journal-title":"Foods"},{"key":"2241_CR134","first-page":"133","volume":"70","author":"MB Covington","year":"2004","unstructured":"Covington MB. Omega-3 fatty acids. Am Fam Physician. 2004;70:133\u201340.","journal-title":"Am Fam Physician"},{"key":"2241_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/frym.2021.601068","volume":"9","author":"KA Wierenga","year":"2021","unstructured":"Wierenga KA, Pestka JJ. Omega-3 fatty acids and inflammation\u2014you are what you eat. Front Young Minds. 2021;9:1\u20137.","journal-title":"Front Young Minds"},{"key":"2241_CR136","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3390\/nu12041179","volume":"12","author":"AC Zhang","year":"2020","unstructured":"Zhang AC, Singh S, Craig JP, Downie LE. Omega-3 fatty acids and eye health: opinions and self-reported practice behaviors of optometrists in Australia and New Zealand. Nutrients. 2020;12:1179.","journal-title":"Nutrients"},{"key":"2241_CR137","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/jop.2024.0160","volume":"41","author":"S Hong","year":"2025","unstructured":"Hong S, Woo M, Eom Y, Kim HK, Yoon KC, Na KS, et al. A multicenter, randomized, clinical trial assessing the effect of rTG-omega 3 supplementation on meibomian gland dysfunction patients after cataract surgery rTG-omega 3 for meibomian gland dysfunction. J Ocul Pharmacol Ther. 2025;41:65\u201374.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2241_CR138","first-page":"5208","volume":"60","author":"M Oydanich","year":"2019","unstructured":"Oydanich M, Greiner JV, Hamrah P, Lin MC, Pistilli M, Maguire MG, et al. Exploratory outcome measures of the DRy Eye Assessment and Management (DREAM) study. Invest Ophth Vis Sci. 2019;60:5208.","journal-title":"Investig Ophth Vis Sci"},{"key":"2241_CR139","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jtos.2019.08.002","volume":"18","author":"M Hussain","year":"2020","unstructured":"Hussain M, Shtein RM, Pistilli M, Maguire MG, Oydanich M, Asbell PA, et al. The dry eye assessment and management (DREAM) extension study\u2014a randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease. Ocul Surf. 2020;18:47\u201355.","journal-title":"Ocul Surf"},{"key":"2241_CR140","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.18240\/ijo.2021.11.08","volume":"14","author":"YJ Jo","year":"2021","unstructured":"Jo YJ, Lee JS. Effects of dietary high dose DHA omega-3 supplement in dry eye with meibomian gland dysfunction. Int J Ophthalmol. 2021;14:1700\u20136.","journal-title":"Int J Ophthalmol"},{"key":"2241_CR141","doi-asserted-by":"publisher","DOI":"10.17511\/jooo.2018.i04.04","author":"C Jain","year":"2018","unstructured":"Jain C, Malik V, Bowry R. Role of omega-3 fatty acids in meibomian gland dysfunction. Trop J Ophthalmol Otolaryngol. 2018;3(4):79.","journal-title":"Ophthalmology"},{"key":"2241_CR142","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1097\/ICO.0000000000000940","volume":"35","author":"AT Epitropoulos","year":"2016","unstructured":"Epitropoulos AT, Donnenfeld ED, Shah ZA, Holland EJ, Gross M, Faulkner WJ, et al. Effect of oral re-esterified omega-3 nutritional supplementation on dry eyes. Cornea. 2016;35:1185\u201391.","journal-title":"Cornea"},{"key":"2241_CR143","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3109\/02713683.2015.1122810","volume":"41","author":"R Bhargava","year":"2016","unstructured":"Bhargava R, Chandra M, Bansal U, Singh D, Ranjan S, Sharma S. A randomized controlled trial of omega 3 fatty acids in rosacea patients with dry eye symptoms. Curr Eye Res. 2016;41:1274\u201380.","journal-title":"Curr Eye Res"},{"key":"2241_CR144","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/ICO.0000000000000446","volume":"34","author":"C Malhotra","year":"2015","unstructured":"Malhotra C, Singh S, Chakma P, Jain AK. Effect of oral omega-3 fatty acid supplementation on contrast sensitivity in patients with moderate meibomian gland dysfunction: a prospective placebo-controlled study. Cornea. 2015;34:637\u201343.","journal-title":"Cornea"},{"issue":"4","key":"2241_CR145","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/ICO.0000000000000366","volume":"34","author":"DR Korb","year":"2015","unstructured":"Korb DR, Blackie CA, Finnemore VM, Douglass T. Effect of using a combination of lid wipes, eye drops, and omega-3 supplements on meibomian gland functionality in patients with lipid deficient\/evaporative dry eye. Cornea. 2015;34(4):407\u201312.","journal-title":"Cornea"},{"key":"2241_CR146","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2147\/CIA.S48955","volume":"8","author":"A Olenik","year":"2013","unstructured":"Olenik A, Jimenez-Alfaro I, Alejandre-Alba N, Mahillo-Fernandez I. A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction. Clin Interv Aging. 2013;8:1133\u20138.","journal-title":"Clin Interv Aging"},{"key":"2241_CR147","first-page":"336","volume":"106","author":"MS Macsai","year":"2008","unstructured":"Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc. 2008;106:336\u201356.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2241_CR148","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/jamaophthalmol.2024.1482","volume":"142","author":"Y Eom","year":"2024","unstructured":"Eom Y, Jun I, Jeon HS, Lim DH, Lee H, Hwang HS, et al. Re-esterified triglyceride omega-3 fatty acids in dry eye disease with meibomian gland dysfunction: a randomized clinical trial. JAMA Ophthalmol. 2024;142:617\u201324.","journal-title":"JAMA Ophthalmol"},{"key":"2241_CR149","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-1-4020-8831-5_5","volume":"49","author":"JX Kang","year":"2008","unstructured":"Kang JX, Weylandt KH. Modulation of inflammatory cytokines by omega-3 fatty acids. Subcell Biochem. 2008;49:133\u201343.","journal-title":"Subcell Biochem"},{"key":"2241_CR150","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/ICO.0b013e3181f22e03","volume":"30","author":"JC Wojtowicz","year":"2011","unstructured":"Wojtowicz JC, Butovich I, Uchiyama E, Aronowicz J, Agee S, McCulley JP. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. Cornea. 2011;30:308\u201314.","journal-title":"Cornea"},{"key":"2241_CR151","volume":"12","author":"M Al-Namaeh","year":"2020","unstructured":"Al-Namaeh M. A systematic review of the effect of omega-3 supplements on meibomian gland dysfunction. Ther Adv Ophthalmol. 2020;12:2515841420952188.","journal-title":"Ther Adv Ophthalmol"},{"key":"2241_CR152","first-page":"CD011016","volume":"12","author":"LE Downie","year":"2019","unstructured":"Downie LE, Ng SM, Lindsley KB, Akpek EK. Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease. Cochrane Database Syst Rev. 2019;12:CD011016.","journal-title":"Cochrane Database Syst Rev"},{"key":"2241_CR153","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.plefa.2018.03.004","volume":"132","author":"JK Innes","year":"2018","unstructured":"Innes JK, Calder PC. Omega-6 fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids. 2018;132:41\u20138.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2241_CR154","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0753-3322(02)00253-6","volume":"56","author":"AP Simopoulos","year":"2002","unstructured":"Simopoulos AP. The importance of the ratio of omega-6\/omega-3 essential fatty acids. Biomed Pharmacother. 2002;56:365\u201379.","journal-title":"Biomed Pharmacother"},{"key":"2241_CR155","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/ICO.0b013e318033d79b","volume":"26","author":"A Pinna","year":"2007","unstructured":"Pinna A, Piccinini P, Carta F. Effect of oral linoleic and gamma-linolenic acid on meibomian gland dysfunction. Cornea. 2007;26:260\u20134.","journal-title":"Cornea"},{"key":"2241_CR156","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.clae.2007.12.001","volume":"31","author":"KH Kokke","year":"2008","unstructured":"Kokke KH, Morris JA, Lawrenson JG. Oral omega-6 essential fatty acid treatment in contact lens associated dry eye. Cont Lens Anterior Eye. 2008;31:141\u20136.","journal-title":"Cont Lens Anterior Eye J Br Cont Lens Assoc"},{"key":"2241_CR157","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/OPX.0000000000001826","volume":"99","author":"A Ng","year":"2022","unstructured":"Ng A, Woods J, Jahn T, Jones LW, Sullivan Ritter J. Effect of a novel omega-3 and omega-6 fatty acid supplement on dry eye disease: a 3-month randomized controlled trial. Optom Vis Sci. 2022;99:67\u201375.","journal-title":"Optom Vis Sci"},{"key":"2241_CR158","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.769132","volume":"8","author":"K Liu","year":"2021","unstructured":"Liu K, Chan YK, Peng X, Yuan R, Liao M, Liang J, et al. Improved dry eye symptoms and signs of patients with meibomian gland dysfunction by a dietary supplement. Front Med Lausanne. 2021;8:769132.","journal-title":"Front Med Lausanne"},{"key":"2241_CR159","first-page":"2508","volume":"101","author":"X Peng","year":"2021","unstructured":"Peng X, Li YJ, Yau YQ, Liao M, Liu KC, Yuan RL, et al. Treatment efficacy of dietary supplement Licofor for dry eye associated with meibomian gland dysfunction. Zhonghua Yi Xue Za Zhi. 2021;101:2508\u201313.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2241_CR160","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.796951","volume":"8","author":"L Tian","year":"2021","unstructured":"Tian L, Wen Y, Li S, Zhang P, Wang Y, Wang J, et al. Benefits and safety of astaxanthin in the treatment of mild-to-moderate dry eye disease. Front Nutr. 2021;8:796951.","journal-title":"Front Nutr"},{"key":"2241_CR161","doi-asserted-by":"publisher","first-page":"1061818","DOI":"10.3389\/fnut.2023.1061818","volume":"10","author":"WY Yu","year":"2023","unstructured":"Yu WY, Chan LYL, Chung A, Lee PH, Woo GC. Bilberry-containing supplements on severe dry eye disease in young and middle-aged adults: a 3-month pilot analysis. Front Nutr. 2023;10:1061818.","journal-title":"Front Nutr"},{"key":"2241_CR162","first-page":"770","volume":"43","author":"G Yinli","year":"2023","unstructured":"Yinli G, Haihong L, Shijing D, Ying D, Peng Z, Zhiqun W, et al. Dry eye disease due to meibomian gland dysfunction treated with Pinggan Yuyin Qingre formula: a stratified randomized controlled trial. J Tradit Chin Med. 2023;43:770\u20139.","journal-title":"J Tradit Chin Med"},{"key":"2241_CR163","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jgr.2014.07.002","volume":"39","author":"HW Bae","year":"2015","unstructured":"Bae HW, Kim JH, Kim S, Kim M, Lee N, Hong S, et al. Effect of Korean Red Ginseng supplementation on dry eye syndrome in glaucoma patients\u2014a randomized, double-blind, placebo-controlled study. J Ginseng Res. 2015;39:7\u201313.","journal-title":"J Ginseng Res"},{"key":"2241_CR164","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/10408690590957188","volume":"46","author":"I Higuera-Ciapara","year":"2006","unstructured":"Higuera-Ciapara I, Felix-Valenzuela L, Goycoolea FM. Astaxanthin: a review of its chemistry and applications. Crit Rev Food Sci Nutr. 2006;46:185\u201396.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"2241_CR165","doi-asserted-by":"crossref","unstructured":"Chu W-k, Cheung SC, Lau RA, Benzie IF. Bilberry (Vaccinium myrtillus L.). Herb Med Biomolec Clin Aspects. 2011; 55\u201372.","DOI":"10.1201\/b10787-5"},{"key":"2241_CR166","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jgr.2015.04.009","volume":"39","author":"SM Lee","year":"2015","unstructured":"Lee SM, Bae BS, Park HW, Ahn NG, Cho BG, Cho YL, et al. Characterization of Korean Red Ginseng (Panax ginseng Meyer): history, preparation method, and chemical composition. J Ginseng Res. 2015;39:384\u201391.","journal-title":"J Ginseng Res"},{"key":"2241_CR167","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jtos.2020.05.007","volume":"19","author":"A Muntz","year":"2021","unstructured":"Muntz A, Sandford E, Claassen M, Curd L, Jackson AK, Watters G, et al. Randomized trial of topical periocular castor oil treatment for blepharitis. Ocul Surf. 2021;19:145\u201350.","journal-title":"Ocul Surf"},{"key":"2241_CR168","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1016\/S0161-6420(02)01262-9","volume":"109","author":"E Goto","year":"2002","unstructured":"Goto E, Shimazaki J, Monden Y, Takano Y, Yagi Y, Shimmura S, et al. Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction. Ophthalmology. 2002;109:2030\u20135.","journal-title":"Ophthalmology"},{"key":"2241_CR169","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/bjophthalmol-2020-317506","volume":"106","author":"AL Li","year":"2022","unstructured":"Li AL, Li SL, Kam KW, Young AL. Randomised assessor-masked trial evaluating topical manuka honey (Optimel) in treatment of meibomian gland dysfunction. Br J Ophthalmol. 2022;106:777\u201380.","journal-title":"Br J Ophthalmol"},{"key":"2241_CR170","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jtos.2019.11.009","volume":"18","author":"JP Craig","year":"2020","unstructured":"Craig JP, Cruzat A, Cheung IMY, Watters GA, Wang MTM. Randomized masked trial of the clinical efficacy of MGO Manuka Honey microemulsion eye cream for the treatment of blepharitis. Ocul Surf. 2020;18:170\u20137.","journal-title":"Ocul Surf"},{"key":"2241_CR171","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/cxo.12524","volume":"100","author":"JM Albietz","year":"2017","unstructured":"Albietz JM, Schmid KL. Randomised controlled trial of topical antibacterial Manuka (Leptospermum species) honey for evaporative dry eye due to meibomian gland dysfunction. Clin Exp Optom. 2017;100:603\u201315.","journal-title":"Clin Exp Optom"},{"key":"2241_CR172","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/ojo.OJO_205_2016","volume":"11","author":"TN Maher","year":"2018","unstructured":"Maher TN. The use of tea tree oil in treating blepharitis and meibomian gland dysfunction. Oman J Ophthalmol. 2018;11:11\u20135.","journal-title":"Oman J Ophthalmol"},{"key":"2241_CR173","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ajo.2021.04.009","volume":"229","author":"S Zarei-Ghanavati","year":"2021","unstructured":"Zarei-Ghanavati S, Nooghabi MJ, Zamani G. Comparison of the effect of tea tree oil shampoo with regular eyelid shampoo in meibomian gland dysfunction treatment. Am J Ophthalmol. 2021;229:45\u201351.","journal-title":"Am J Ophthalmol"},{"key":"2241_CR174","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4103\/ejos.ejos_66_24","volume":"118","author":"HM Ahmed","year":"2025","unstructured":"Ahmed HM, Bayoumy ASM, Abousaif WS, Gad EA. The effect of tea tree oil gel versus regular eyelid shampoo in the treatment of meibomian gland dysfunction. J Egypt Ophthalmol Soc. 2025;118:183\u20139.","journal-title":"J Egypt Ophthalmol Soc"},{"key":"2241_CR175","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5301\/ejo.5001011","volume":"28","author":"EI Postorino","year":"2018","unstructured":"Postorino EI, Rania L, Aragona E, Mannucci C, Alibrandi A, Calapai G, et al. Efficacy of eyedrops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye. Eur J Ophthalmol. 2018;28:25\u201331.","journal-title":"Eur J Ophthalmol"},{"key":"2241_CR176","volume":"11","author":"M Nejabat","year":"2017","unstructured":"Nejabat M, Reza SA, Zadmehr M, Yasemi M, Sobhani Z. Efficacy of green tea extract for treatment of dry eye and meibomian gland dysfunction; a double-blind randomized controlled clinical trial study. J Clin Diagn Res. 2017;11:NC05-NC8.","journal-title":"J Clin Diagn Res"},{"key":"2241_CR177","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/cxo.13148","volume":"104","author":"EC Sandford","year":"2021","unstructured":"Sandford EC, Muntz A, Craig JP. Therapeutic potential of castor oil in managing blepharitis, meibomian gland dysfunction and dry eye. Clin Exp Optom. 2021;104:315\u201322.","journal-title":"Clin Exp Optom"},{"key":"2241_CR178","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1167\/iovs.05-0275","volume":"46","author":"YY Gao","year":"2005","unstructured":"Gao YY, Di Pascuale MA, Li W, Liu DT, Baradaran-Rafii A, Elizondo A, et al. High prevalence of demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005;46:3089\u201394.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2241_CR179","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1097\/ICO.0000000000002506","volume":"39","author":"D Chen","year":"2020","unstructured":"Chen D, Wang J, Sullivan DA, Kam WR, Liu Y. Effects of terpinen-4-ol on meibomian gland epithelial cells in vitro. Cornea. 2020;39:1541\u20136.","journal-title":"Cornea"},{"key":"2241_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2022.101733","volume":"45","author":"JP Craig","year":"2022","unstructured":"Craig JP, Bitton E, Dantam J, Jones L, Ngo W, Wang MTM. Short-term tolerability of commercial eyelid cleansers: a randomised crossover study. Cont Lens Anterior Eye. 2022;45:101733.","journal-title":"Contact Lens Anterior Eye"},{"key":"2241_CR181","first-page":"1065","volume":"72","author":"RA Bonakdar","year":"2005","unstructured":"Bonakdar RA, Guarneri E. Coenzyme Q10. Am Fam Physician. 2005;72:1065\u201370.","journal-title":"Am Fam Physician"},{"key":"2241_CR182","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.jff.2013.08.011","volume":"5","author":"SN Senanayake","year":"2013","unstructured":"Senanayake SN. Green tea extract: chemistry, antioxidant properties and food applications\u2013a review. J Funct Foods. 2013;5:1529\u201341.","journal-title":"J Funct Foods"},{"key":"2241_CR183","unstructured":"A phase I\/II, randomized, double-masked, vehicle-controlled study of the safety, tolerability, and efficacy of AXR-270 topical eyelid cream in treating posterior blepharitis associated with meibomian gland dysfunction (NCT04469998) In: ClinicalTrials.gov. National Library of Medicine (US). 2020. https:\/\/clinicaltrials.gov\/study\/NCT04469998. Accessed 29 Aug 2025."},{"key":"2241_CR184","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jtos.2023.07.002","volume":"29","author":"SL Watson","year":"2023","unstructured":"Watson SL, Jones LW, Stapleton F, Hinds M, Ng A, Tan J, et al. Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction: a vehicle-controlled, randomized clinical trial. Ocul Surf. 2023;29:537\u201346.","journal-title":"Ocul Surf"},{"key":"2241_CR185","first-page":"1535-A0260","volume":"63","author":"J Tan","year":"2022","unstructured":"Tan J, Jia TN, Bosworth C, Briggs N, Gleeson MT, Stapleton F. The effect of a novel selenium disulphide-containing topical treatment on ocular signs in individuals with meibomian gland dysfunction. Investig Ophth Vis Sci. 2022;63:1535-A0260.","journal-title":"Investig Ophth Vis Sci."},{"key":"2241_CR186","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jtos.2024.11.008","volume":"35","author":"LE Downie","year":"2025","unstructured":"Downie LE, Craig JP, Stapleton F, Tan J, Jones LW, Ng A, et al. Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction over six months of treatment: a phase 2, vehicle-controlled, randomized extension trial. Ocul Surf. 2025;35:15\u201324.","journal-title":"Ocul Surf"},{"key":"2241_CR187","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jtos.2025.01.015","volume":"36","author":"F Stapleton","year":"2025","unstructured":"Stapleton F, Jia T, DePuy V, Bosworth C, Gleeson M, Tan J. The effect of a biweekly novel selenium sulfide-containing topical treatment in symptomatic contact lens wearers: an exploratory study. Ocul Surf. 2025;36:190\u20137.","journal-title":"Ocul Surf"},{"key":"2241_CR188","unstructured":"A phase 3, multicenter, vehicle-controlled, randomized study to evaluate the efficacy, safety, and tolerability of AZR-MD-001 in patients with abnormal meibomian gland function and associated symptoms of dry eye disease (DED) (NCT06329791) In: ClinicalTrials.gov. National Library of Medicine (US). 2024. https:\/\/clinicaltrials.gov\/study\/NCT06329791. Accessed 29 Aug 2025."},{"key":"2241_CR189","unstructured":"A Phase 2 Multicenter, Double-masked, randomized, vehicle-controlled, parallel study to evaluate the safety, efficacy and pharmacokinetics of CBT-006 in patients with meibomian gland dysfunction (NCT04884243) In: ClinicalTrials.gov. National Library of Medicine (US). 2021. https:\/\/clinicaltrials.gov\/study\/NCT04884243. Accessed 29 Aug 2025."},{"key":"2241_CR190","unstructured":"A phase 2 multicenter, double-masked, randomized, vehicle-controlled, parallel study to evaluate the safety, efficacy and pharmacokinetics of CBT-008 in patients with meibomian gland dysfunction (NCT05261386) In: ClinicalTrials.gov. National Library of Medicine (US). 2022. https:\/\/clinicaltrials.gov\/study\/NCT05261386. Accessed 29 Aug 2025."},{"key":"2241_CR191","unstructured":"A multi-center, double-masked, randomized, vehicle-controlled study of the efficacy and safety of HY02 ointment in subjects with inflamed meibomian gland dysfunction (NCT03888378) In: ClinicalTrials.gov. National Library of Medicine (US). 2019. https:\/\/clinicaltrials.gov\/study\/NCT03888378. Accessed 29 Aug 2025."},{"key":"2241_CR192","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jamaophthalmol.2013.195","volume":"131","author":"F Amparo","year":"2013","unstructured":"Amparo F, Dastjerdi MH, Okanobo A, Ferrari G, Smaga L, Hamrah P, et al. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol. 2013;131:715\u201323.","journal-title":"JAMA Ophthalmol"},{"key":"2241_CR193","first-page":"862","volume":"16","author":"A Enriquez-de-Salamanca","year":"2010","unstructured":"Enriquez-de-Salamanca A, Castellanos E, Stern ME, Fernandez I, Carreno E, Garcia-Vazquez C, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis. 2010;16:862\u201373.","journal-title":"Mol Vis"},{"key":"2241_CR194","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jtos.2013.04.004","volume":"11","author":"S Hagan","year":"2013","unstructured":"Hagan S, Tomlinson A. Tear fluid biomarker profiling: a review of multiplex bead analysis. Ocul Surf. 2013;11:219\u201335.","journal-title":"Ocul Surf"},{"key":"2241_CR195","first-page":"2283","volume":"42","author":"A Solomon","year":"2001","unstructured":"Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283\u201392.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2241_CR196","unstructured":"The efficacy and safety of topical vitamin D drop on meibomian gland function in patients with meibomian gland dysfunction (NCT05495958) In: ClinicalTrials.gov. National Library of Medicine (US). 2022. https:\/\/clinicaltrials.gov\/study\/NCT05495958. Accessed 29 Aug 2025."},{"key":"2241_CR197","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-017-0482-7","volume":"17","author":"R Arita","year":"2017","unstructured":"Arita R, Kawashima M, Ito M, Tsubota K. Clinical safety and efficacy of vitamin D3 analog ointment for treatment of obstructive meibomian gland dysfunction. BMC Ophthalmol. 2017;17:84.","journal-title":"BMC Ophthalmol"},{"key":"2241_CR198","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/ICO.0000000000003400","volume":"43","author":"K Hassanpour","year":"2024","unstructured":"Hassanpour K, Langari F, Akbarzadeh AR, Kanavi MR, Barani M, Kheiri B, et al. Safety and efficacy of topical vitamin D in the management of dry eye disease associated with meibomian gland dysfunction: a placebo-controlled double-blind randomized controlled trial. Cornea. 2024;43:552\u201363.","journal-title":"Cornea"},{"key":"2241_CR199","unstructured":"Effect of sunflower lecithin supplementation on meibomian gland function in adults with dry eye disease (NCT06058559) In: ClinicalTrials.gov. National Library of Medicine (US). 2023. https:\/\/clinicaltrials.gov\/study\/NCT06058559. Accessed 29 Aug 2025."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02241-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02241-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02241-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:02:26Z","timestamp":1777006946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02241-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":199,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2241"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02241-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"14 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Outside of this work, the university (J.P.C.) has received research funding from Alcon, Azura Ophthalmics, Photon Therapeutics and TRG Natural Pharmaceuticals. Consultancy fees and\/or honoraria have been received by J.P.C. from the following: Alcon, Apogee, Bausch+Lomb and Laboratoires Th\u00e9a. The authors declare no other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"J.M.C.: data curation, writing \u2013 original draft and writing \u2013 review and editing; R.M.: data curation, conception: writing \u2013 original draft and writing \u2013 review and editing; C.J.J.: data curation, writing \u2013 original draft and writing \u2013 review and editing; K.B.: data curation, writing \u2013 original draft and writing \u2013 review and editing; M.T.M.W.: conception, visualisation and writing \u2013 review and editing; and J.P.C.: conception, visualisation, funding, supervision and writing \u2013 review and editing.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}